Inclisiran, which The Medicines Co. is developing with Alnylam, prevents production of PCSK9, the same protein targeted by two drugs that were the subject of a major patent lawsuit ruling last week. The company plans regulatory filings starting later this year.
The firm announced that it closed a $22 million Series C2 round, following a $25 million Series C1 round that it had closed last June, led by Asian investors.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The deal will focus on discovery, development and commercialization of CNS and eye drugs and also includes development of two C5-targeting drugs in liver disease. The companies have an existing partnership centered on NASH drugs.
The drug is the first approved treatment for the condition, as well as the first siRNA drug to win the agency's approval.
Firm raises funding for RNAi therapy's clinical development from group of Chinese funds.
Gilead just lost one candidate, Bristol-Myers has licensed another; the race for non-alcoholic fatty liver disease drugs continues, as many companies eye its potential for a blockbuster drug.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.